Abstract
We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies’ good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.
Keywords: APDS; COVID19; IEI; SARS-CoV-2; activated PI3K delta syndrome (APDS); long-lasting infection; monoclonal antibody; remdesivir.
【저자키워드】 SARS-CoV-2, COVID19, monoclonal antibody, Remdesivir, APDS, IEI, activated PI3K delta syndrome (APDS), long-lasting infection, 【초록키워드】 Efficacy, SARS-COV-2 infection, monoclonal antibody, Infection, viral shedding, Remdesivir, SARS-CoV-2 virus, monoclonal antibodies, virus, Viral, Patient, therapeutic agents, Swab, genotyping, wild type, neutralizing monoclonal antibodies, monoclonal, administration, Tolerability, multiple therapeutic agents, syndrome, other treatments, pauci-symptomatic, PI3K, clearance, first positive, tested, described, affected, treated, activated, reducing, long-lasting, multiple therapeutic agent, the SARS-CoV-2 virus, 【제목키워드】 Prolonged, LINE,